Cancer researchers claim ‘extraordinary results’ using T-cell therapy Scientists are claiming “extraordinary” success with engineering immune cells to target a specific type of blood cancer in their first clinical trials.
Revisiting CAR-T Cells for Treating HIV Shows Promise The rise in the development of chimeric antigen receptor (CAR) T cells for use against various forms of cancer has been well
Third-generation CAR molecules were produced by incorporating two or more co-stimulatory molecules into the CAR construct. These CARs are not necessarily more superior than second-generation (results from comparative studies are
Fourth-generation CARs enter the scene. Also known as ‘T cell redirected for universal cytokine-mediated killing’ (TRUCKs), these demonstrated improvements in anti-tumour efficacy.
Seattle cancer trial ‘very good news’ for young patients More than 90 percent of children and young adults with acute lymphoblastic leukemia, or ALL, are in remission after treatment as
In 2014 CAR-T therapy received Breakthrough Drug designation from the US Food and Drug Administration for relapsed and/or refractory acute lymphoblastic leukaemia.
In 2012 Emily Whitehead became the first paediatric patient to be treated with CAR-T therapy. She is still in remission today.
In 2010 the first clinical trial of CAR-T therapy was reported, using second-gen CARs and targeted at CD19 in non-Hodkin's lymphoma, a blood cancer. CD19 is still the predominant CAR-T cell
In the late 1990s it was found that CARs would be more effective if they were designed with the addition of another molecule - a ‘co-stimulatory’ molecule to work alongside of
In 1993 Dr Zelig Eshhar and colleagues at the Weizmann Institute in Israel engineer the first-generation CAR molecule. Dr Eshhar had spent time in the United States in 1990 with
